Oxford Specialist Handbook: Myeloproliferative Neoplasms

Our understanding of myeloproliferative neoplasms (MPN) disorders, a group of clonal haematological malignancies characterized by excessive accumulation of one or more myeloid cell lineages, has grown considerably over the past four decades.

Myeloproliferative Neoplasms offers a detailed evidence-based guide to MPNs in an easily accessible format, structured to facilitate learning specialist information by presenting core information in 'bite size' chunks.

Each chapter summarises the state-of-the art preclinical and clinical knowledge, and its impact on the clinical management of patients with MPNs. This practical guide, written by experts in the field, is essential reading for oncologists, haematologists, and other health care professionals interested in the field of MPNs.

Tariq I. Mughal, Professor of Medicine in Hematology/Oncology, Tufts University Medical Center, Boston, MA, USA,Tiziano Barbui, Professor of Hematology, Scientific Director, Research Foundation Ospedali Riuniti di Bergamo, Italy

Following training in haematology/oncology and stem cell transplantation at Imperial College London, Professor Tariq I Mughal has held haematology/oncology leadership roles in cancer centres of excellence in London, Manchester and Denver. From an early stage in his career, he has been interested in precision haematologic cancer medicine and breast cancer. He now practices in Boston and London, and is a member of many learned societies. He is a professor of medicine and founder of Alpine Oncology Foundation dedicated to improve haematologic cancer care in economically challenged countries. He has published over 130 peer-reviewed scientific publications, 30 book chapters and authored/edited 13 books on cancers.

Following training inhematology/oncology in Padova, Professor Tiziano Barbui was appointed initially as a Professor, and later as the head of the department of Haematology at the (then) Ospedale Riuniti, and now Papa Giovanni XXIII, in Bergamo (Italy). He is a past-President of the Italian Society of Haematology, and chair of the Lupus Anticoagulant Subcommittee of the International Society of Thrombosis and Haemostasis. He currently leads the Italian GIMEMA group and is the co-chair of the European-Leukemia-Net working group on Myeloproliferative Disorders. He has published over 450 peer-reviewed scientific publications and authored/edited several books and chapters.

1. History of the myeloproliferative neoplasms, Tariq I. Mughal and Tiziano Barbui
2. Genomic landscape of myeloproliferative neo-plasms, Srinivas K. Tantravahi, Jamshid S. Khorashad, and Michael W.Deininger
3. Pathogenesis of myeloproliferative neoplasms, Angela G. Fleischman and Richard A. Van Etten
4. Haematopathology of myeloproliferative neoplasms, Hans Michael Kvasnicka and J?ergen Thiele
5. Prognostic factors of chronic myeloid leukaemia, Michele Baccarani, Fausto Castagnetti, Gabriele Gugliotta, Francesca Palandri, Simona Soverini, and Gianantonio Rosti
6. Molecular risk stratification of Myeloproliferative Neoplasms, Paola Guglielmelli and Alessandro M. Vannucchi
7. Chronic myeloid leukaemia, Tariq I. Mughal
8. Polycythaemia vera, Tiziano Barbui and Guido Finazzi
9. Myelofibrosis, Claire Harrison, Yan Beauverd, and Donal McLorran
10. Essential thrombocythemia, Carlos Besses, Beatriz Bellosillo, and Alberto Alvarez-Larr?n
11. Systemic mastocytosis, Jason Gotlib
12. Myelodysplastic syndromes/myeloproliferative neoplasms, Eric Padron, David Sallman, Tariq I. Mughal, and Alan F. List
13. Eosinophilia-associated myeloproliferative neoplasms, Andreas Reiter and Nicholas C. P. Cross
14. Transformation of myeloproliferative neoplasms to acute leukaemia, Omar Abdelwahab, Raajit Rampal, Catriona Jamieson, and Tariq I. Mughal
15. Monitoring efforts in myeloproliferative neoplasms, Daniel Egan and Jerald P. Radich
16. Stem cell transplantation for BCR-ABL1-postive and negative myeloproliferative neoplasms, Alessandro Rambaldi and Nicholas Kr?ger
17. Assessment of disease burden in patients with myeloproliferative neoplasms, Holly L. Geyer, Deepti Radia, Nicholas Sarlis, and Ruben A. Mesa
18. Clinical trials in bcr-abl1-negative myeloproliferative neo-plasms, Giovanni Barosi and Gianni Tognoni